Piramal Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Other Operating Revenue for the year ending 31-Mar-2023.
Going by the draft papers, Piramal Pharma will issue fully paid-up equity shares of the company by way of a rights issue to its existing eligible shareholders for an amount aggregating up to Rs 1,050 crore.